Synchron raises $200 million to power non-surgical brain interface commercialization

New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally

Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001

IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China

Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506

Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions

Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun

Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun

Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)

Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico